Return to Emergent BioSolutions

    Facility Spotlight: Winnipeg, Manitoba, Canada

    01.18.2023

    For more than 30 years, our Winnipeg, Manitoba (Canada) site has offered a broad range of expertise for drug substance and drug product manufacturing. The 150,000-sq.ft. facility manufactures polyclonal hyperimmune products, plasma therapeutics, lipoproteins, and mRNA products, and houses a SA25 aseptic filling workcell — a gloveless, robotic isolator ideal for high-value biologic products.


    Learn more about how our Winnipeg site is equipped to support your next clinical or commercial drug candidate.

    Emergent CDMO

    Video Video Library

    Related Stories

    07.20.2023

    Outsourced Pharma Capacity Update | July 2023

    Kevin Yarnall, Sr. Manager, Manufacturing, presented Emergent's manufacturing capabilities and available capacity at its...

    READ MORE

    06.28.2023

    4 Steps for a Smooth Tech Transfer When Working with a CDMO

    In our recent article with BioPharma Dive, Emergent's Shelly Buhay, Director of MS&T and Dan Perrin, Director of Manufacturing...

    READ MORE

    04.17.2020

    Webinar: Finding Solutions for public health threats: COVID-19

    What are innovators doing to speed up the path to treating and preventing COVID-19?

    The novel coronavirus has quickly taken...

    READ MORE